Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

ABOUT US

Carl June, M.D., Chair

Chief Executive Officer and Chairman

A headshot of Mark J. Gergen

Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022 and named Chairman of the Board of Directors in February 2023. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being named President and Chief Business Officer in July 2020. He has been a member of our Board of Directors since 2018. Mr. Gergen was previously the Senior Vice President and Chief Operating Officer of Halozyme, Inc. and Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc. Previously he served in senior management positions, including as Senior Vice President of Corporate Development, at Amylin Pharmaceuticals, Inc. He also served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc., and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.

A headshot of Mark J. Gergen